AbbVie Inc. (4ABD.XC)
| Previous close | 149.28 |
| Open | 149.28 |
| Bid | 159.56 x 0 |
| Ask | 160.24 x 0 |
| Day's range | 149.28 - 149.28 |
| 52-week range | 125.90 - 162.10 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 277.24B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 47.69 |
| EPS (TTM) | 3.13 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 5.73 (3.84%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
PR NewswireU.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.3 SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.
PR NewswireAbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash (Offer Price).
ZacksPharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
